Triclosan causes spontaneous abortion accompanied by decline of estrogen sulfotransferase activity in humans and mice

Xiaoli Wang1,2*, Xiaojiao Chen1,3,4*, Xuejiao Feng2, Fei Chang2, Minjian Chen1,4, Yankai Xia1,3,4 & Ling Chen1,2

Triclosan (TCS), an antibacterial agent, is identified in serum and urine of humans. Here, we show that the level of urinary TCS in 28.3% patients who had spontaneous abortion in mid-gestation were increased by 11.3-fold (high-TCS) compared with normal pregnancies. Oral administration of TCS (10 mg/kg/day) in mice (TCS mice) caused an equivalent urinary TCS level as those in the high-TCS abortion patients. The TCS-exposure from gestation day (GD) 5.5 caused dose-dependently fetal death during GD12.5–16.5 with decline of live fetal weight. GD15.5 TCS mice appeared placental thrombus and tissue necrosis with enhancement of platelet aggregation. The levels of placenta and plasma estrogen sulfotransferase (EST) mRNA and protein in TCS mice or high-TCS abortion patients were not altered, but their EST activities were significantly reduced compared to controls. Although the levels of serum estrogen (E2) in TCS mice and high-TCS abortion patients had no difference from controls, their ratio of sulfo-conjugated E2 and unconjugated E2 was reduced. The estrogen receptor antagonist ICI-182,780 prevented the enhanced platelet aggregation and placental thrombosis and attenuated the fetal death in TCS mice. The findings indicate that TCS-exposure might cause spontaneous abortion probably through inhibition of EST activity to produce placental thrombosis.

Spontaneous abortion is the most common complication of human pregnancy and 10–15% of clinical pregnancies end in it1. Recently, a growing body of evidence has supported an association between exposure to environmental endocrine disrupters and spontaneous abortion. Triclosan (TCS), an antibacterial agent, is widely used in soaps, toothpastes, first-aid products, fabrics and plastic goods3,4. This compound has been identified in the mother’s milk, the plasma of people in Sweden and Australia5,6 and the urine of people in the United States7.

There are several biological activities of TCS that are unrelated to its antibacterial action. For example, TCS reduces the level of thyroid hormone in weanling rats8,9, and exhibits estrogenic and androgenic activities in breast cancer cells10. Triclosan is known to inhibit sulfonation of phenolic xenobiotics in human liver cytosol and is structurally related to inhibitors of estrogen sulfotransferase (EST)11. James et al. has reported that TCS can inhibit the activity of sheep placental cytosolic EST to reduce the levels of both estradiol and estrone sulfonation12.

EST, encoded by SULT1E1, is expressed in human, bovine and murine placentas during mid- to late gestation to catalyze the sulfoconjugation of estrogen (E2) at the 3-hydroxyl position13–15. The discrete localization of EST at the interface of the fetal-maternal blood exchange suggests that EST may play a critical role in modulating E2 activity in both fetal and maternal plasma16. Either genetic or chemical inactivation of placental EST may cause pregnancy failure or intrauterine growth retardation in humans and other mammals17. Exposure to TCS at an average dose of 3.2 mg/kg has been reported to decrease the survival of postnatal mice18. However, the effects of TCS-exposure during mid- to late gestation on the maintenance of pregnancy and fetal development have not yet been reported.

To determine the influence of TCS on the process of pregnancy, an epidemiological investigation was primarily designed to examine the level of urinary TCS in normal pregnancy and spontaneous abortion patients in
mid-gestation. According to the level of urinary TCS in spontaneous abortion patients, we prepared the model of pregnant mouse exposed to TCS, in which the fetal survival and development were examined during mid- to late gestation. In addition, placental structure, the levels of reproductive hormones and thyroid hormones, the expression and activity of EST were further examined in spontaneous abortion patients and TCS-exposed pregnant mice. Our results indicated that the exposure of TCS in humans and mice might cause spontaneous abortion in mid-gestation probably through the inhibition of EST activity leading to placental thrombosis and degeneration.

Results
Spontaneous abortion patients in mid-gestation with a high level of urinary TCS. Measuring TCS and its metabolites in urine represents an important biomonitoring tool for exposure assessment. The baseline excretion of TCS in urine was published by Sandborg-Englund et al.20. In the present study, all 452 eligible females provided urine for analysis. There were 113 spontaneous abortion patients and 339 normal gestations in mid-gestation weeks 14–24, with a mean age of 28.30 ± 4.24 years and 27.55 ± 3.90 years, respectively. The smoking status in abortion patients had no difference from control group (P = 0.492). Meanwhile, there was a difference in the body mass index (BMI) between abortion patients (21.89 ± 2.60 kg/m²) and controls (23.49 ± 3.62 kg/m²; P = 0.038). In abortion patients, the detectable rate of urinary TCS (57.52%; Table 1) was 1.76-fold higher as compared to control group (32.74%). In addition, the mean concentration of urinary TCS in abortion patients (2.50 ng/ml) was increased approximately 2.53 folds compared to control group (0.99 ng/ml). The crude and adjusted odds ratios (ORs) for the association between the TCS exposure level and spontaneous abortion were shown in the Table 2. A dose-response relationship was observed for TCS exposure (adjusted ORs for increasing exposure levels = 1.00, 2.00 (1.08–3.70), 2.36 (1.29–4.34); P value of test for trend = 0.003). Particularly, the level of urinary TCS in 28.3% abortion patients (11.21 ng/ml) was increased approximately 11.3-fold compared to mean of controls (0.99 ng/ml).

TCS-exposure causes spontaneous abortion in mid-gestation. To examine the influence of TCS on the maintenance of pregnancy and fetal development, 3-month-old mice were treated with TCS daily by gavage at doses of 1, 10 and 100 mg/kg/day (termed 1-TCS mice, 10-TCS mice and 100-TCS mice, respectively) from gestation day (GD) 5.5. The level of urinary TCS was measured at GD10.5 and GD15.5, respectively. As shown in Fig. 1a, the level of urinary TCS in GD10.5 10-TCS mice was equivalent to that in abortion patients with a high level of urinary TCS (28.3%). However, the level of urinary TCS showed no significant difference between GD10.5 and GD15.5 10-TCS mice (data not shown).

The TCS-exposure caused a dose-dependent increase in the fetal death (Fig. 1b). In comparison with GD15.5 control mice, the number of live fetuses was reduced by approximately 30% in 100-TCS mice (P < 0.001, n = 20; Fig. 1c) and 15% in 10-TCS mice (P = 0.030, n = 20), respectively. The incidence of spontaneous abortion in 100-TCS mice and 10-TCS mice reached 80% (P < 0.001, n = 20; Fig. 1d) and 60% (P = 0.015, n = 20), respectively. In addition, the body weight of live fetuses was significantly reduced in 100-TCS mice (P < 0.001, n = 20; Fig. 1e) and 10-TCS mice (P = 0.018, n = 20) compared with controls.

To determine the time of TCS-induced spontaneous abortion, we further examined the numbers of live and dead fetuses during GD10.5–16.5. As shown in Fig. 1f, the reduction of live fetuses was primarily observed at GD13.5 (P = 0.015, n = 10) and was gradually aggravated during GD14.5 (P < 0.001, n = 10) and GD16.5 (P < 0.001, n = 10). Consistently, the number of dead or reabsorbed fetuses showed a progressive increase from GD13.5 (P = 0.004, n = 10) to GD16.5 (P < 0.001, n = 10).

TCS-exposure enhances placental thrombosis. Notably, the placentas were dark in GD15.5 10-TCS mice and 100-TCS mice, but not in 1-TCS mice (Fig. 2a). The placental weight in GD15.5 100-TCS mice had a slight increase compared to control mice (P = 0.015, n = 20; Fig. 2b). The histological observation showed the placental

---

**Table 1. Distribution of unadjusted TCS level (ng/ml) in urine.** The LOD of TCS was 0.9 ng/ml. All values below LOD were assigned a value equal to the LOD divided by 2. CI: confidence interval.

| chemical TCS | control | abortion | crude | adjusted |
|--------------|---------|----------|-------|----------|
|              | No.     | No.      | OR(95%CI) | P-value | OR(95%CI) | P-value |
| low          | 228     | 48       | 1.00    | 1.00     | 1.00      | 1.00    |
| median       | 55      | 33       | 2.85(1.67–4.85)* | 1.13E-04 | 2.00(1.08–3.70)* | 0.027  |
| high         | 56      | 32       | 2.71(1.59–4.63)* | 2.52E-04 | 2.36(1.29–4.34)* | 0.006  |
| P-value for trend |        |          | 2.34E-05  |          | 0.003     |         |

**Table 2. Crude and adjusted ORs (95% CIs) for spontaneous abortion by the exposure level of TCS.** ORs are adjusted for BMI, drinking status and creatinine level. *P < 0.05 vs. low-TCS exposure level.
Figure 1. TCS-exposure causes spontaneous abortion in mid-gestation. (a) Levels of TCS in urine of GD10.5 mice exposed to various doses of TCS. Adjusted concentration: adjusted for the creatinine level. (b) Representative picture of fetuses in GD15.5 control mice, mice exposed to 1 mg/kg TCS (1-TCS), 10 mg/kg TCS (10-TCS) and 100 mg/kg TCS (100-TCS). Thick arrows: fetal death; thin arrows: reabsorbed fetuses. (c) Ratio of lost fetuses against total number of fetuses in GD15.5 TCS mice. *P < 0.05 and **P < 0.01 vs. control mice (one way ANOVA). (d) Ratio of spontaneous abortion in GD15.5 control mice and TCS mice. *P < 0.05 and **P < 0.01 vs. control mice (one way ANOVA). (e) Body weight (g) of live fetuses in GD15.5 control mice and TCS mice. *P < 0.05 and **P < 0.01 vs. control mice (one way ANOVA). (f) Average number of live (squares) and dead (circles) fetuses in control mice (open symbols) and TCS mice (filled symbols) at GD10.5-16.5. *P < 0.05 and **P < 0.01 (live fetuses) vs. control mice; ***P < 0.01 (dead fetuses) vs. control mice (two way ANOVA).
thrombus (Fig. 2c–iii,iv) and hemorrhage (Fig. 2c–v) with tissue necrosis (Fig. 2c–vi) and atrophy of junctional zone in approximately 50% of 10-TCS mice and nearly all 100-TCS mice.

TCS-exposure alters the levels of reproductive hormones and thyroid hormones. The levels of serum estrogen (E2), progesterone (P4) and β-human chorionic gonadotropin (β-HCG) were investigated in 100-TCS mice and abortion patients. The levels of E2 ($P = 0.358$, $n = 20$; Table 3), P4 ($P = 0.196$, $n = 20$) and β-HCG ($P = 0.419$, $n = 20$) in GD12.5 TCS mice did not differ significantly from control mice. The levels of P4 ($P < 0.001$, $n = 20$) and β-HCG ($P < 0.001$, $n = 20$) were significantly reduced in GD15.5 100-TCS mice compared to controls, while E2 level had no significant difference between the both groups ($P = 0.105$, $n = 20$). However, the levels of sulfo-conjugated (S-E2) were reduced in TCS mice (GD12.5: $P = 0.008$, $n = 20$; GD15.5: $P = 0.005$, $n = 20$), while the levels of unconjugated E2 (free E2) were observably increased in TCS mice (GD12.5: $P = 0.027$, $n = 20$; GD15.5: $P = 0.021$, $n = 20$) compared to controls. Thus, the ratio of S-E2 and free E2 in TCS mice (GD12.5: $1.47 \pm 0.83$; GD15.5: $1.51 \pm 0.57$) was lower than that in control mice (GD12.5: $5.53 \pm 1.32$, $P = 0.004$; GD15.5: $5.12 \pm 1.07$, $P < 0.001$). In addition, the levels of serum thyroxine (T4) and triiodothyronine (T3) in TCS mice (GD12.5: $P = 0.048$, $n = 20$; GD15.5: $P = 0.026$, $n = 20$) were lower than those in control mice.

Figure 2. TCS-exposure causes placental thrombosis and hemorrhage. (a) Representative picture of placentas in GD15.5 control mice and TCS mice. (b) Placenta weight (g) in GD15.5 control mice and TCS mice. *$P < 0.05$ vs. control mice (one way ANOVA). (c) Representative picture of placental histological observation by hematoxylin and eosin staining in GD15.5 control mice and TCS mice. Lab: labyrinthine zone; Jun: junctional zone; Dec: deciduas. Thick arrows: thrombi; thin arrow: tissue necrosis; hollow arrow: hemorrhage area. Scale bars = 100 μm.
Table 3. Levels of hormones in serum. *P < 0.05, **P < 0.01 vs. control. +P < 0.05, ++P < 0.01 vs. GD12.5 control. +P < 0.05, ++P < 0.01 vs. GD15.5 control.

| Hormones | Human | mouse | human | mouse | human | mouse |
|----------|-------|-------|-------|-------|-------|-------|
|         | control | low-TCS | high-TCS | control | 100-TCS | control | 100-TCS |
| E2 (pg/ml) | 238.77 | 165.69* | 201.18 | 15.52 | 18.42 | 24.81** | 20.70 |
| free E2 (pg/ml) | – | – | – | 3.18 | 5.57* | 5.23* | 6.85* |
| S-E2 (pg/ml) | – | – | – | 17.24 | 8.60** | 25.88 | 9.92** |
| P4 (pg/ml) | 75.84 | 27.24** | 20.88** | 11.90 | 10.13 | 21.13** | 6.17** |
| β-HCG (mIU/ml) | 35.26 | 11.07** | 8.75** | 5.73 | 4.72 | 7.09 | 2.59** |
| T4 (ng/ml) | – | – | – | 21.08 | 12.83* | 19.51 | 9.13* |
| T3 (ng/ml) | – | – | – | 1.76 | 0.88* | 2.10 | 1.17** |

In the low-TCS and high-TCS abortion patients, the levels of P4 (low-TCS: P < 0.001, n = 48; high-TCS: P < 0.001, n = 32) and β-HCG (low-TCS: P < 0.001, n = 48; high-TCS: P < 0.001, n = 32) were clearly lower than those in normal gestation (control group, n = 339). The level of E2 in low-TCS abortion patients was lower than control (P = 0.012, n = 48), whereas in high-TCS abortion patients had no difference from control group (P = 0.074, n = 32).

TCS-exposure suppresses EST activity to increase activated E2. The level of placental SULT1E1 mRNA in control mice was increased starting from GD10.5 and became highly abundant at GD15.5 (Fig. 3a). In comparison with control mice, the levels of placental SULT1E1 mRNA in 100-TCS mice did not differ significantly at GD11.5 (P = 0.121, n = 10), GD12.5 (P = 0.236, n = 10) and GD13.5 (P = 0.063, n = 10) followed by a detectable decline at GD14.5-16.5 (P < 0.001, n = 10). Consistently, the levels of EST protein in placenta (Fig. 3b) or plasma (Fig. 3c) in GD15.5 100-TCS mice were lower than those in control mice (P < 0.001, n = 10), although had no significant difference between GD12.5 100-TCS mice and control mice (placenta: P = 0.162, n = 10; plasma: P = 0.085, n = 10). The activity of EST was further examined by radiochemical extraction assay when the amount of EST protein was corrected to be equal. Notably, the activities of placental and plasma EST in either GD12.5 (P < 0.001, n = 10; Fig. 3d,e) or GD15.5 100-TCS mice (P < 0.001, n = 10) were significantly reduced compared to control mice.

In comparison with control group of normal gestation 22–24 weeks, the level of plasma EST protein was reduced in low-TCS (P = 0.013, n = 10; Fig. 3f) and high-TCS abortion patients (P < 0.001, n = 10). Although the EST protein in high-TCS abortion patients tended to be less than that in low-TCS abortion patients, the group comparison failed to reach significance (P = 0.111, n = 10). Importantly, the activity of plasma EST in high-TCS abortion patients was lower than in control group (P < 0.001, n = 10; Fig. 3g) and low-TCS abortion patients (P = 0.027, n = 10).

TCS-exposure enhances platelet aggregation to cause placental thrombosis. To test whether the TCS-induced increase in activated E2 is involved in the placental thrombosis and spontaneous abortion, we examined blood coagulation state in GD15.5 100-TCS mice. The results showed that the levels of plasma fibrin degradation product (FDP) (P = 0.002, n = 8; Table 4) and ADP-induced platelet aggregation (P = 0.020, n = 8) were increased in 100-TCS mice with the decline of prothrombin time (PT) (P = 0.019, n = 8) and activated partial thromboplastin time (APTT) (P = 0.032, n = 8) compared to controls, which could be corrected by the estrogen receptor (ER) antagonist ICI 182,780 when administered on GD12.5-15.5 (FDP: P = 0.009, n = 8; ADP-induced platelet aggregation: P = 0.042, n = 8; PT: P = 0.005, n = 8; APTT: P = 0.048, n = 8). As expected, the administration of ICI 182,780 prevented the placental thrombosis in GD15.5 10-TCS and 100-TCS mice (Fig. 4a) and partially reduced the fetal death in 100-TCS mice (P < 0.001, n = 10; Fig. 4b). Although the blockade of ER by ICI 182,780 had a tendency to rescue the decline of fetal body weight, the group comparison with vehicle-treated 100-TCS mice failed to reach significance (P = 0.066, n = 10; Fig. 4c).

Discussion

The present study provides the first in vivo evidence that exposure to TCS can cause spontaneous abortion in humans and mice. This conclusion is deduced mainly from the following results. The level of urinary TCS in 28.3% high-TCS spontaneous abortion patients (11.21 ng/ml) was increased by 11.3-fold compared to normal pregnancies (0.99 ng/ml). The National Health and Nutrition Examination Survey collected 2,517 urine samples in a representative US population and detected urinary TCS in 74.6% of the samples at concentrations of 2.4–3790 μg/L. Based on species differences, by conversion of an uncertainty factor (100 times), we inferred that the level of urinary TCS in mice exposed to 10 mg/kg TCS was equivalent to that in high-TCS abortion patients, while in mice exposed to 100 mg/kg TCS was equivalent to the high exposure level of US population. According to the level of urinary TCS in abortion patients, we prepared the model of mice exposed to TCS from gestation day (GD) 5.5. More importantly, the exposure to TCS at doses of 10 and 100 mg/kg in pregnancy mice caused an approximately 60–80% spontaneous abortion with the growth retardation of fetuses during GD12.5–16.5.

SULT1E1 expression has been determined in the placenta of humans, cows and mice during mid- to late gestation.13,14,21 Consistent with an earlier report by Tong et al.,16 the expression of placental EST in mice was increased from GD12.5 and reached an approximately 6-fold increase at GD15.5. In 100-TCS mice, the levels of placental SULT1E1 mRNA and EST protein in GD12.5 did not differ significantly from control mice, while in GD15.5
Figure 3. TCS-exposure suppresses the activity of EST. (a) Level of placental SULT1E1 mRNA in GD10.5-16.5 control mice and 100-TCS mice. **P < 0.01 vs. control mice (two way ANOVA). (b,c) Representative immunoblotting and corresponding densitometric analysis showing the levels of placental and plasma EST protein in GD12.5 and GD15.5 control mice and 100-TCS mice. The blots in panel band were performed on the same blot membranes and shown as cropped images. **P < 0.01 vs. GD12.5 control mice. ##P < 0.01 vs. GD15.5 control mice (two way ANOVA). (d,e) Activities of placental and plasma EST in GD12.5 and GD15.5 control mice and 100-TCS mice. **P < 0.01 vs. GD12.5 control mice; ##P < 0.01 vs. GD15.5 control mice (two way ANOVA). (f) Representative immunoblotting analysis showing the levels of plasma EST protein in control, low-TCS and high-TCS abortion patients. *P < 0.05 and **P < 0.01 vs. control group (one way ANOVA). The blots in panel band were performed on the same blot membranes and shown as cropped images. Full-length versions of all western blots are presented in Supplementary Figure 1. (g) Activity of plasma EST in control, low-TCS and high-TCS abortion patients. **P < 0.01 vs. control group; *P < 0.05 vs. low-TCS abortion patients (one way ANOVA).
were reduced compared to controls. One possibility is that the placental tissue necrosis in GD15.5 100-TCS mice leads to the reduction of EST. In addition, the level of plasma EST protein had no significant difference between low-TCS and high-TCS abortion patients, although it was lower than that in control group. It is conceivable that the TCS-exposure does not affect the EST expression in mice and human. One principal finding in this study is that the activity of EST was significantly reduced in high-TCS abortion patients and GD12.5-15.5 TCS mice. James et al. have reported that the inhibitory effect of TCS on sheep placental EST activity was mixed competitive/uncompetitive actions12. Moreover, a potent human EST inhibitor 4′OHCB7911 is a highly potent inhibitor of sheep EST12, providing evidence that animal and human EST respond similarly to TCS inhibition. Therefore, our results suggest that the exposure of TCS can inhibit the activity of EST in humans and mice.

Placenta provides nearly all of E2 in the forms of sulfo-conjugated E2 (S-E2) and estrone, which are present at much higher concentrations than the unconjugated E2 (free E2). The discrete localization of EST at the interface of the fetal-maternal blood exchange suggests that EST may play a critical role in modulating E2 activity in both fetal and maternal plasma. The levels of serum E2 in SULT1E1 knockout mice from DG12.5 to DG 17.5 were significantly elevated, which were associated with the increase in the levels of free E2 in the amniotic fluids at DG14.5 and DG17.517. Thus, it is conceivable that the decline of EST activity during mid- to late gestation through reducing the degradation and excretion of E2 can elevate the level of activated E2. Although the levels of serum E2 at DG12.5 and DG15.5 had no difference between TCS mice and control mice, the ratio of S-E2 and free E2 in TCS mice was lower than that in control mice, implying an increase of the activated E2 in TCS mice. It is possibility that the decline of serum P4 level in TCS mice arises from the placental degeneration and failure.

Table 4. Coagulation state in GD15.5 mice. *P < 0.05, **P < 0.01 vs. control. #P < 0.05, ##P < 0.01 vs. 100-TCS mice.

|               | control | 100-TCS | ICI     | 100-TCS+ICI |
|---------------|---------|---------|---------|-------------|
| FDP (ng/ml)   | 15.25±2.50 | 24.67±1.53** | 11.91±2.83 | 17.50±0.97** |
| PT (s)        | 17.60±0.88  | 14.23±1.74*  | 21.38±2.19* | 19.80±1.56** |
| APPT (s)      | 22.25±2.38  | 16.40±2.88*  | 25.31±3.44  | 23.55±3.03*  |
| platelet aggregation (%) | 32.75±3.40 | 59.33±9.06*  | 27.51±2.51  | 34.50±5.39*  |

Figure 4. Effects of ER antagonist in TCS-induced placental thrombosis and spontaneous abortion.
(a) Effects of ICI 182,780 (ICI) on TCS-caused placental thrombosis in GD15.5 TCS mice. Block arrow indicates thrombi. Scale bars = 100 μm. (b,c) Effects of ICI 182,780 (ICI) on fetal loss and reduced body weight (g) of live fetuses in GD15.5 100-TCS mice. *P < 0.01 vs. control mice; **P < 0.01 vs. 100-TCS mice (two way ANOVA).
Another important finding in the present study is that the platelet aggregation and platelet activation were enhanced in TCS mice, which could be blocked by the ER antagonist. In particular, the blockade of ER reduced remarkably the placental thrombus and hemorrhage in GD15.5 TCS mice. The over-activation of ER has been reported to induce platelet aggregation in human through cascading Src, Pyk2 and PI3-kinase or increasing the integrin affinity for fibrinogen to reduce the threshold of platelet activation22. E2 intake in women can increase the procoagulant factors and decrease the anticoagulant factors21-25. In addition, the SULT1E1 knockout mice showed placental thrombus and fetal death during mid- to late gestation46,47, in which the treatment with E2 is able to exacerbate the fetal loss phenotype in a dose-dependent manner. Furthermore, higher dose of E2 has been demonstrated to cause placental thrombosis and an increase in fetal death incidence in wild-type mice. Therefore, our results give an indication that the inhibition of EST by TCS enhances the platelet aggregation and platelet activation through increasing activated E2 to create a procoagulant state and cause the placental hemorrhage and necrosis.

Interestingly, the ER antagonist could attenuate the fetal death in TCS mice. A possible explanation is that the increase of activated E2 in TCS mice causes the placental degeneration and failure leading to spontaneous abortion. The delivery of oxygen and nutrients to the developing fetus is highly dependent on the maintenance of high uterine blood flow. Wood et al. have reported the presence of estradiol-3-sulfate in the plasma of fetal sheep at concentrations of approximately 1 ng/ml14. The sulfated estrogen formed in the placenta is transferred to the fetus, as a major source of E226. In E2-responsive tissues, steroid sulfatase can hydrolyze sulfo-conjugated E2 into active E227. It is clear that E2 is required for normal fetal development26,29. E2 potently stimulates fetal ACTH secretion28. The increase in fetal ACTH and cortisol concentrations can further elevate fetal stress responsiveness and accelerate fetal maturation. In addition, E2 could stimulate thyroid growth by elevating the expression of thyrotropin (TSH)91. Therefore, it is proposed that TCS through suppressed EST activity leads to the decline in the transformation of circulating E2 from maternal plasma to the fetus, delaying fetal development and maturation. On the other hand, the exposure to TCS (30 mg/kg) only can decrease the level of serum T4 in male rats4. An earlier study9 reported that the exposure to TCS (10–50 mg/kg) could decrease the serum total T4 and T3 in pregnant rats, which contributes to the diminished growth and development of fetuses32. Our results showed the decline of serum T3 and T4 in TCS mice. Because the ER antagonist partially rescued the decline of fetal body weight in TCS mice, thus it is indicated that the reduction of thyroid hormone in TCS mice is an initiating event for the growth retardation of fetuses.

TCS is widely used in personal care products. Stanley et al. reported that the concentration of TCS that causes substantial inhibition of EST is in the range of the environmental exposure level14. The present study provides in vivo evidence that the exposure of human or mice to TCS, at least partially, through inhibiting EST activity might cause spontaneous abortion and growth retardation of fetuses. This study is the first to implicate that the activation of EST is required for the maintenance of pregnancy and fetal development during mid to late gestation in human.

Materials and Methods

Collection of spontaneous abortion cases. The subjects were volunteers from the NJMU Birth Cohort at affiliated hospitals of Nanjing Medical University. The Institutional Review Board of Nanjing Medical University approved the protocols. All of the studies involving human subjects were performed under full compliance with government policies and the Helsinki Declaration. After explanation of the study procedures and clarification of the questions raised, all of the subjects gave their informed consent. A complete physical examination, including measurement of the height and weight, was performed. A questionnaire was used to collect information, including personal background, lifestyle factors, occupational and environmental exposures, genetic risk factors, sexual and reproduction statuses, medical history, and physical activity. Controls were females who had no history of spontaneous abortion and had at least one living child. The cases were females who had medically unexplained spontaneous abortion in mid-gestation weeks 14–2435. We excluded the subjects with certain known factors related to spontaneous abortion, such as chromosomal abnormality, uterine abnormalities, autoimmune diseases, infection, and occupational exposure to certain toxins suspected to be associated with spontaneous abortion from this study. All of the participants for final analyses, including 113 eligible cases and 339 eligible controls in mid-gestation weeks 14–24, claimed that their life styles and environment had not changed for several months leading up to sample collection. Urine, serum and plasma samples were collected within 12 hours after spontaneous abortion. These samples were frozen at −20 °C until phenol analysis.

Measurement of urinary TCS. The urinary concentration of TCS was measured with ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) (Milford, MA, USA). Firstly, urine samples were incubated in 1 M ammonium acetate buffer solution (pH = 5.0) for hydrolyzation with β-glucuronidase/sulfatase (20000 units/ml) overnight. After hydrolysis, the phenols were extracted and preconcentrated with solid phase extraction (SPE) (500 mg/3 ml, Supelclean, USA), and determined with UPLC (Acquity UPLCTM BEH C18 column, 1.7 μm, 2.1 × 100 mm) electrospray ionization (negative ion mode)-MS/MS. The limit of detection (LOD) was 0.8 ng/ml. The intra- and inter-day precisions for TCS were between 9% and 38% and the recoveries were between 99% and 138% at spiked concentration of 2, 20 ng/mL. Quality control samples were analyzed in parallel with unknown samples in each analytical series. Creatinine (CR) concentrations were analyzed for correcting the phenols concentration variations caused by fluctuated urine concentration and dilution. CR concentrations of urine were measured with an automated chemistry analyzer (7020 Hitachi, Japan).

Animals and drug administration. All of the animal experimental procedures followed the guidelines of the Laboratory Animal Research of Nanjing Medical University and were approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. Three-month-old female and male mice (Oriental Bio Service Inc., Nanjing), weighing approximately 30–35 g, were used in the study. All of the mice were housed under a 12/12 hour light/dark cycle (lights on at 0600 hour) with free access to food and tap water. Detection of
a vaginal plug was chosen to indicate day 0.5 of gestation (GD0.5). TCS (Sigma, St. Louis, Mo.) was dissolved in dimethylsulfoxide (DMSO), and then diluted was with corn oil. The dams were given oral administration of TCS at doses of 1, 10 and 100 mg/kg per day. Control mice were treated with vehicle at the same volume. During the treatment with TCS, the dams did not show significant abnormality in body weight. A pellet of the ER antagonist ICI182,780 (Sigma, St. Louis, Mo.) with 1.5 mg/12 days of release was implanted at GD12.5. Control mice received placebo pellet implantation.

**Histological examination.** The placenta was fixed in 4% paraformaldehyde and then dehydrated through a graded series of alcohol, cleared in xylene and embedded in paraffin wax. Sections (5-μm thick) deparaffinized were stained with hematoxylin and eosin (HE) and observed using a conventional light microscope (Olympus DP70; Tokyo, Japan).

**Measurement of serum hormones.** The blood samples were collected within 12 hours after spontaneous abortion in humans. Orbital blood (500 μl) of mice was obtained under anesthetized conditions with chloralhydrate (400 mg/kg, i.p.) at 9 hours (1600–1700) after the administration of TCS. Levels of serum total E2, progesterone (P4), β-human choricron gonadotropin (β-HCG), thyroxine (T4) and triiodothyronine (T3) were examined using a radioimmunoassay (RIA) kit provided by the National Hormone and Peptide Programme (Baltimore, MD). The intra- and inter-assay coefficients of variation were 6% and 5.8% for E2, 5.8% and 8.4% for P4, 3.4% and 12.3% for β-HCG, 5.1% and 8.6% for T4, 2.9% and 8.3% for T3, respectively. The lowest detectable levels were 2 pg/ml for E2, 0.2 ng/ml for P4, 2 μIU/ml for β-HCG, 5.0 ng/ml for T4, 0.1 ng/ml for T3, respectively. The plasma was extracted with ethanol to preserve the water-soluble steroid including sulfo-conjugated E2 (S-E2) or using hexane/ethyl acetate (3:2, vol/vol) to obtain unconjugated E2 (free E2), according to the method of Wood et al. Then, the levels of S-E2 and free E2 in extraction were measured by enzyme-linked immunoassay (Oxford Chemical Co., Oxford, MI). The intraassay coefficient of variation in this enzyme-linked immunoassay was 8.1%.

**Assessment of coagulation state.** The anticoagulated blood samples using sodium citrate were collected. Fibrin degradation product (FDP) was measured by Cusabio rat FDP ELISA assay kit (Cusabio, Wuhan, China) according to the manufacturer’s instructions. To estimate platelet aggregation, platelet rich plasma (PRP) was prepared by centrifugation (250 g) for 10 min, and then tested by the turbidimetric technique according to the method of Mustard et al. The platelet aggregation was induced using ADP at a final concentration of 10μM. The prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using calcium rabbit brain thromboplastin and kaolin platelet substitute techniques (Diagen Diagnostic Reagent Ltd., Oxon, UK). The prothrombin time was 0.9 s. The activated partial thromboplastin time was 36.2 s.

**Western blot analysis.** We performed Western blot analysis as described previously. Briefly, the placenta was homogenized to obtain protein samples. Next, proteins (50μg) were resolved by SDS-PAGE, transferred onto PVDF membrane, probed with a rabbit anti-mouse EST polyclonal antibody (1:200; Santa Cruz Biotechnology, CA, USA), and labeled with an HRP-labeled goat anti-rabbit IgG (1:5000; Millipore, Billerica, MA). Signal quantification was carried out using Quantity One image software (Bio-Rad).

**Reverse transcription quantitative polymerase chain reaction (RT-qPCR).** Total RNA was extracted from the placentas using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA (1 μg) was used for reverse transcription using high-capacity cDNA of the reverse transcription kit RT (TaKaRa Biotechnology Co., Ltd) according to the instructions. The primer sequences of SULT1E1 and GAPDH mRNA were designed according to earlier publications. RT-qPCR was performed using a Light Cycler Fast Start DNA Master SYBR Green I kit and an ABI Prism 7300 Sequence Detection System (Applied Biosystems, Foster City, California, USA), and the relative expression of genes was determined using the 2-ΔΔct method with normalization to GAPDH expression. The results were averaged from four sets of independent experiments.

**Assays of EST activity.** EST activities were measured using a radiochemical extraction assay. 3′-Phosphoadenosine-5′-phosphosulfate was purchased from Sigma-Aldrich chemical company (St. Louis, MO), and H4-estradiol (60 Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). Incubation mixtures (0.5 ml) contained 100 mM Tris–HCl (pH 7.4), 5 mM MgCl2, 0.8 mg placental cytosolic protein, 20 μM PAPS, and 2 nM 3H-estradiol (60 Ci/mmol) was purchased from PerkinElmer Life Sciences Inc. (Boston, MA). The reaction was initiated with the addition of PAPS and continued for 30 minutes at 37 °C. The reaction mixture was extracted with 1 ml of dichloromethane and aliquot of the aqueous phase was counted by liquid scintillation counting.

**Statistical analysis.** The group data were expressed as the means ± standard error (SE). All of the statistical analyses were performed using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Differences among the means were analyzed using ANOVA, followed by Bonferroni post-hoc analysis, or Student’s t-test when appropriate. In some cases, logistic regression and chi-squared test were used. Differences at P < 0.05 were considered statistically significant.

**References**

1. Schaeffer, A. J. et al. Comparative genomic hybridization-array analysis enhances the detection of aneuploides and submicroscopic imbalances in spontaneous miscarriages. *Am J Hum Genet* **74**, 1168–1174 (2004).

2. Arbuckle, T. E., Lin, Z. & Mery, L. S. An exploratory analysis of the effect of pesticide exposure on the risk of spontaneous abortion in an Ontario farm population. *Environ Health Perspect* **109**, 851–857 (2001).

3. Clayton, E. M., Todd, M., Dowd, J. B. & Aiello, A. E. The impact of bisphenol A and triclosan on immune parameters in the U.S. population, NHANES 2003–2006. *Environ Health Perspect* **119**, 390–396 (2011).

4. Jones, R. D., Jampani, H. B., Newman, J. L. & Lee, A. S. Triclosan: a review of effectiveness and safety in health care settings. *Am J Infect Control* **28**, 184–196 (2000).
5. Allmeyr, M., Adolfsin-Erci, M., McLachlan, M. S. & Sandborgh-Englund, G. Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. *Sci Total Environ* **372**, 87–93 (2006).

6. Allmeyr, M. et al. The influence of age and gender on triclosan concentrations in Australian human blood serum. *Sci Total Environ* **393**, 162–167 (2008).

7. Calafat, A. M., Ye, X., Wong, L. Y., Reidy, J. A. & Needham, L. L. Urinary concentrations of triclosan in the U.S. population: 2003–2004. *Environ Health Perspect* **116**, 303–307 (2008).

8. Zorrilla, L. M. et al. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. *Toxicol Sci* **107**, 56–64 (2009).

9. Rodriguez, P. E. & Sanchez, M. S. Maternal exposure to triclosan impairs thyroid homeostasis and female pubertal development in Wistar rat offspring. *J Toxicol Environ Health A* **73**, 1678–1688 (2010).

10. Gee, R. H., Charles, A., Taylor, N. & Darbre, P. D. Oestrogenic and androgenic activity of triclosan in breast cancer cells. *J Appl Toxicol* **28**, 78–91 (2008).

11. Kester, M. H. et al. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. *Endocrinology* **141**, 1897–1900 (2000).

12. James, M. O., Li, W., Summerlot, D. P., Rowland-Faux, L. & Wood, C. E. Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta. *Environ Int* **36**, 942–949 (2010).

13. Hoffmann, B., Faller, K., Vielemeier, A., Pauling, K. & Schuler, G. Investigations on the activity of bovine placental oestrogen sulfotransferase and -sulfatase from midgestation to parturition. *Exp Clin Endocrinol Diabetes* **109**, 294–301 (2001).

14. Stanley, E. L., Hume, R., Visser, T. J. & Coughtris, M. W. Differential expression of sulfotransferase enzymes involved in thyroid hormone metabolism during human placental development. *J Clin Endocrinol Metab* **86**, 5944–5955 (2001).

15. Alnouti, Y. & Klaassens, C. D. Tissue distribution and ontogeny of sulfotransferases enzymes in mice. *Toxicol Sci* **93**, 242–255 (2006).

16. Wood, C. E., Gridley, K. E. & Keller-Wood, M. Biological activity of 17beta-estradiol-3-sulfate in ovine fetal plasma and uptake in fetal brain. *Endocrinology* **144**, 599–604 (2003).

17. Tong, M. H. et al. Spontaneous fetal loss caused by placent thrombosis in estrogen sulfotransferase-deficient mice. *Nat Med* **11**, 153–159 (2005).

18. Russell, L. B. & Montgomery, C. S. Use of the mouse spot test to investigate the mutagenic potential of triclosan (Irgasan DP300). *Mutat Res* **79**, 7–12 (1980).

19. Queckenberg, C. et al. Absorption, pharmacokinetics, and safety of triclosan after dermal administration. *Antimicrob Agents Chemother* **54**, 570–572 (2010).

20. Sandborgh-Englund, G., Adolfsin-Erci, M., Oldham, G. & Ekstrand, J. Pharmacokinetics of triclosan following oral ingestion in humans. *J Toxicol Environ Health A* **69**, 1861–1873 (2006).

21. Hirayama, H. et al. Excess estrogen sulfoconjugation as the possible cause for a poor sign of parturition in pregnant cows carrying somatic cell done fetuses. *Reproduction* **136**, 639–647 (2008).

22. Moro, L. et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. *Blood* **105**, 115–121 (2005).

23. Rosendaal, F. R., Helmerhorst, F. M. & Vandebroucke, J. P. Female hormones and thrombosis. *Arterioscler Thromb Vasc Biol* **22**, 201–210 (2002).

24. Scarabini, P. Y. A. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. *Thromb Haemost* **74**, 928–932 (1995).

25. Koh, K. K., Horne, M. K., & Cannon, R. O., 3rd. Effects of hormone replacement therapy on coagulation, fibrinolysis, and oestrogen receptor beta and Src kinase. *Blood* **105**, 115–121 (2005).

26. Wood, C. E. Estrogen/hypothalamus-pituitary-adenal axis interactions in the fetus: The interplay between placenta and fetal brain. *J Soc Gynecol Invest* **12**, 67–76 (2005).

27. Purinton, S. C. & Wood, C. E. Ovine fetal estrogen sulfotransferase in brain regions important for hypothalamus-pituitary-adrenal axis control. *Neuroendocrinology* **71**, 237–242 (2000).

28. Magness, R. K., Parker, C. R., & Rosenfeld, C. R. Systemic and uterine responses to chronic infusion of estradiol-17 beta. *Am J Physiol* **265**, E690–698 (1993).

29. Vagnoni, K. E. et al. Endothelial vasodilator production by uterine and systemic arteries. III. Ovarian and estrogen effects on NO synthase. *Am J Physiol* **275**, H1845–1856 (1998).

30. Wood, C. E. & Saoed, C. J. Influence of estradiol and androstenedione on ACTH and cortisol secretion in the ovine fetus. *J Soc Gynecol Invest* **4**, 279–283 (1997).

31. Banu, S. K., Arosh, J. A., Govindarajulu, P. & Aruldas, M. M. Testosterone and estradiol differentially regulate thyroid growth in Wistar rats from immature to adult age. *Endocr Res* **27**, 447–463 (2001).

32. LaFranchi, S. Thyroid function in the preterm infant. *Thyroid* **9**, 71–78 (1999).

33. Mustard, J. F., Hegardt, B., Rowell, H. C. & Macmillan, R. L. Effect of Adenosine Nucleotides on Platelet Aggregation and Clotting Time. *J Lab Clin Med* **64**, 548–559 (1964).

34. Song, W. C., Qian, Y., Sun, X. & Negishi, M. Cellular localization and regulation of expression of testicular estrogen sulfotransferase. *Endocrinology* **138**, 5006–5012 (1997).

35. Wang, L. Q. & James, M. O. Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product from estradiol-3-sulfate to estradiol-17-sulfate. *J Steroid Biochem Mol Biol* **96**, 367–374 (2005).

Acknowledgements

This study was supported by the National 973 Program (2014CB943303, 2012CBA01305), the National Science Fund for Outstanding Young Scholars (81322039), the National Natural Science Foundation (31171440; 81401204), and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Author Contributions

I.C. and Y.K.X. carried out the analysis of data and manuscript drafting. X.L.W. mainly carried out the experimental design in mice and the measurement of EST activity. X.J.F. participated in the experimental design in human and the measurement of TCS. X.J.F., F.C. and M.J.C. examined the reproductive hormones and placental observation.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, X. et al. Triclosan causes spontaneous abortion accompanied by decline of estrogen sulfotransferase activity in humans and mice. *Sci. Rep.* **5**, 18252; doi: 10.1038/srep18252 (2015).
